Please login to the form below

Not currently logged in
Email:
Password:

drug pricing

This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.

AZ prices severe asthma drug Fasenra below competition

AZ prices severe asthma drug Fasenra below competition

AZ prices severe asthma drug Fasenra below competition. The discounted drug will cost $38, 000 in the first year. ... battle to its competitors by pricing the drug at a discount to GSK’s Nucala (mepolizumab) and Teva’s Cinqair/Cinqaero (reslizumab) -

Latest news

  • Novartis claims EU approval for breast cancer drug Kisqali Novartis claims EU approval for breast cancer drug Kisqali

    hormone receptor-positive, HER2-negative tumours, five months after a green light for the drug in the US. ... In the US, Novartis launched its drug with a flexible pricing scheme that it says undercuts Ibrance, which analysts have suggested is designed

  • FDA clears Pfizer's leukaemia drug Besponsa FDA clears Pfizer's leukaemia drug Besponsa

    FDA clears Pfizer's leukaemia drug Besponsa. The breakthrough treatment is the first CD22-targeted ADC to be approved in the US. ... Pfizer is pricing the drug at just under $170, 000 per typical treatment course, before any discounts or rebates, and

  • Merck CEO resigns from Trump post in Charlottesville protest Merck CEO resigns from Trump post in Charlottesville protest

    more time to LOWER RIPOFF DRUG PRICES!" Merck has not however been among pharma companies singled out for price hikes, and has in fact been very transparent about its pricing strategy. ... The spat comes as the Trump administration is reportedly in the

  • Solid start for Dupixent as Sanofi raises 2017 outlook Solid start for Dupixent as Sanofi raises 2017 outlook

    Sanofi said its new atopic dermatitis drug Dupixent is off to a good start in the US, making 26m in sales in its first full quarter on the market. ... Sanofi's pricing of the drug undercuts closest rival - Roche's Actemra (tocilizumab) - as well as other

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    EU starts investigation of Aspen's cancer drug pricing. Amid reports of price increases of several hundred per cent. ... possible price-fixing among generic medicine drugs in the wake of some very high-profile pricing scandals.

More from news
Approximately 53 fully matching, plus 183 partially matching documents found.

Latest Intelligence

  • Drug pricing

    Healthcare terms - Drug pricing.

  • Risky business for pharma Risky business for pharma

    Chan Lee, North America general counsel, Sanofi, explained: “Drug pricing is a significant risk in our industry, particularly in the US.”Lee also cited “scrutiny of manufacturer interactions with payers, patients, ... PD Villareal, senior vice

  • The gold standard of scientific evidence The gold standard of scientific evidence

    The FDA uses RWE to monitor drug safety as part of the Sentinel project. ... Additionally, RWE is being used to inform. creative drug pricing. When seeking coverage for Kymriah, a new CAR-T therapy, Novartis has an agreement with the Centers for Medicaid

  • US health reforms US health reforms

    One of the things I think industry is worried about is if Congress and the President can’t get a health bill passed, do they turn to drug pricing because that ... Pricing and transparency laws enjoy way more support among the general population than

  • A healthcare landscape going through seismic change A healthcare landscape going through seismic change

    insulation from the looming challenges which now include Brexit and drug pricing in the UK. ... drug phenytoin sodium after it was debranded in 2012.

More from intelligence
Approximately 7 fully matching, plus 26 partially matching documents found.

Latest appointments

  • Pfizer’s Emms takes up ABPI presidency Pfizer’s Emms takes up ABPI presidency

    Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the

  • Bayer's Martin Hesse moves to Daiichi Sankyo Europe

    Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge. “

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A roadmap to strategic drug pricing

    A roadmap to strategic drug pricing. The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... A roadmap to strategic drug pricing.

  • Pricing's Point Man

    Pricing's Point Man. In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney.

  • EY Life Sciences

    A roadmap to strategic drug pricing. ... In 2016, a renewed focus on value-based drug pricing, staunch competition across key therapeutic battlegrounds and consolidated payer clout may exacerbate existing growth gaps, resulting in a continued feverish

  • Ed Schoonveld - new article

    Ed Schoonveld - new article. Following the publication of the new edition of The Price of Global Health, Ed Schoonveld writes about the industry's need for new drug pricing model. ... Does the drug industry need a new pricing model? Read Ed Schoonveld's

  • The Price of Global Health

    Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation.

More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics